Lauren Harshman

About Lauren Harshman
  • Immunotherapy has come of age with the approval of Sipuleucel-T (Provenge) and the introduction of ipilimumab (Yervoy) and other similar immune modulators into clinical trials for advanced metastatic prostate cancer.
  • Dr. Harshman will study the biologic activities of a genetically-modified prostate tumor cell vaccine in the setting of Xtandi (enzalutamide) therapy for advanced, metastatic prostate cancer.
  • These translational investigations, while developing a new therapy for patients, will also result in a biological understanding of the mechanisms of sensitivity and resistance to immunotherapy for prostate cancer. What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.

What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.

Award

2013 PCF Young Investigator

Lauren Harshman, MD

Dana-Farber Cancer Institute

Mentors:

Philip Kantoff, MD and Christopher Sweeney, MBBS

Project Title:

Clinical exploration of innovative targeted and immune modulating therapies in prostate cancer